Celon Pharma SA

As of June 30, 2026, Celon Pharma SA carries a market capitalization of 1.06B, placing it among publicly traded companies globally. Its enterprise value stands at 1.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Celon Pharma SA's next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Celon Pharma SA has 53.91M shares outstanding.

As of June 30, 2026, Celon Pharma SA trades at a trailing price-to-earnings ratio of 9.29.

As of June 30, 2026, Celon Pharma SA trades at an EV/EBITDA multiple of 42.19 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. These enterprise value multiples are built on an enterprise value of 1.16B versus a market cap of 1.06B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Celon Pharma SA maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.76, indicating elevated leverage, while an interest coverage ratio of 7.55 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Celon Pharma SA posted a return on equity (ROE) of 25.07, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 18.22, measuring how efficiently the asset base is converted into earnings.

Over the twelve months ended June 30, 2026, Celon Pharma SA recorded 14.52M in income tax expense.

As of the close on October 22, 2026, Celon Pharma SA's stock has declined approximately 12.75% over the past 52 weeks. The 50-day moving average sits at 20.50, while the 200-day moving average is 20.90.

These figures cover the twelve months ended June 30, 2026. EBITDA reached 27.43M, while operating income came in at -10.48M.

As of June 30, 2026, Celon Pharma SA holds 34.36M in cash and equivalents against 128.44M in total debt, resulting in a net debt position of 48.85M. Total book value stands at 498.57M, with working capital of 33.78M providing operational flexibility.

Celon Pharma SA produced 27.29M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -57.44M in capital expenditures, free cash flow totaled -30.15M - equivalent to -0.58 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.93: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.31, meaning Celon Pharma SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.